Use of emgliflozin in the prevention of cardotoxicity.The EMPACARD - PILOT TRIAL. 12 - months Follow -up
Abstract
Anthracycline-based chemotherapy remains a cornerstone in the treatment of several common malignancies, including breast cancer, lymphoma, and sarcoma.
However, its use is associated with a significant risk of cancer therapy-related cardiac dysfunction (CTRCD). Identifying effective cardioprotective strategies is therefore a critical priority in cardio-oncology. have suggested that sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as empagliflozin, may offer cardioprotective benefits in this setting.
Demonstrate that empagliflozin may serve as a promising strategy to mitigate anthracycline-induced CTRCD.
The EMPACARD PILOT Trial is a prospective case–control study enrolling breast cancer patients scheduled to receive four cycles of doxorubicin at 60 mg/m² . The HFA-ICOS score was used to identify patients at high or very high risk of CTRCD. Patients with diabetes mellitus or heart failure with preserved ejection fraction (HFpEF) at baseline received empagliflozin (10 mg/day), starting seven days before anthracycline administration and continuing for 12 months. Patients without baseline diabetes or HFpEF served as controls. The primary endpoints were a decrease in left ventricular ejection fraction (LVEF) of ≥10% to a final value < 50% or a reduction in global longitudinal strain (GLS) of at least 15% from baseline at any point during the study. Secondary endpoints included cardiovascular mortality, cardiovascular hospitalization, or heart failure. Exploratory endpoints…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.